{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:14:57Z","timestamp":1793970897792,"version":"4.8.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Dongcheng District Outstanding Talent Nurturing Program","award":["2022-dchrcpyzz-69"],"award-info":[{"award-number":["2022-dchrcpyzz-69"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-A-021"],"award-info":[{"award-number":["2022-PUMCH-A-021"]}]},{"name":"Research and Translation Application of Beijing Clinical Diagnostic Technologies Funds from Beijing Municipal Commission of Science and Technology","award":["Z211100002921016"],"award-info":[{"award-number":["Z211100002921016"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s00277-025-06324-y","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T14:47:58Z","timestamp":1743259678000},"page":"2559-2561","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Spontaneous remission of iMCD-TAFRO: a case report"],"prefix":"10.1007","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9490-1760","authenticated-orcid":false,"given":"Yuchong","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7776-3642","authenticated-orcid":false,"given":"Miaoyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congwei","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0860-9625","authenticated-orcid":false,"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4549-0694","authenticated-orcid":false,"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"issue":"16","key":"6324_CR1","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1182\/blood.2019000931","volume":"135","author":"A Dispenzieri","year":"2020","unstructured":"Dispenzieri A, Fajgenbaum DC (2020) Overview of Castleman disease. Blood 135(16):1353\u20131364. https:\/\/doi.org\/10.1182\/blood.2019000931","journal-title":"Blood"},{"key":"6324_CR2","doi-asserted-by":"publisher","unstructured":"Fajgenbaum DC, June CH (2020) Cytokine Storm. N Engl J Med, 383(23): pp. 2255\u20132273. https:\/\/doi.org\/10.1056\/NEJMra2026131","DOI":"10.1056\/NEJMra2026131"},{"issue":"20","key":"6324_CR3","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1182\/blood-2018-07-862334","volume":"132","author":"F van Rhee","year":"2018","unstructured":"van Rhee F et al (2018) International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood 132(20):2115\u20132124. https:\/\/doi.org\/10.1182\/blood-2018-07-862334","journal-title":"Blood"},{"issue":"9","key":"6324_CR4","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/S1470-2045(14)70319-5","volume":"15","author":"F van Rhee","year":"2014","unstructured":"van Rhee F et al (2014) Siltuximab for multicentric Castleman\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 15(9):966\u2013974. https:\/\/doi.org\/10.1016\/S1470-2045(14)70319-5","journal-title":"Lancet Oncol"},{"issue":"10","key":"6324_CR5","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1002\/ajh.26292","volume":"96","author":"Y Nishimura","year":"2021","unstructured":"Nishimura Y et al (2021) Validated international definition of the thrombocytopenia, Anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease. Am J Hematol 96(10):1241\u20131252. https:\/\/doi.org\/10.1002\/ajh.26292","journal-title":"Am J Hematol"},{"issue":"12","key":"6324_CR6","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1182\/blood-2016-10-746933","volume":"129","author":"DC Fajgenbaum","year":"2017","unstructured":"Fajgenbaum DC et al (2017) International, evidence-based consensus diagnostic criteria for HHV-8-negative\/idiopathic multicentric Castleman disease. Blood 129(12):1646\u20131657. https:\/\/doi.org\/10.1182\/blood-2016-10-746933","journal-title":"Blood"},{"issue":"5","key":"6324_CR7","first-page":"320","volume":"51","author":"K Takai","year":"2010","unstructured":"Takai K et al (2010) [Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, Ascites and hepatosplenomegaly]. [Rinsho Ketsueki] Japanese J Clin Hematol 51(5):320\u2013325","journal-title":"[Rinsho Ketsueki] Japanese J Clin Hematol"},{"issue":"1","key":"6324_CR8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.hoc.2017.09.009","volume":"32","author":"T Igawa","year":"2018","unstructured":"Igawa T, Sato Y (2018) TAFRO syndrome. Hematol Oncol Clin N Am 32(1):107\u2013118. https:\/\/doi.org\/10.1016\/j.hoc.2017.09.009","journal-title":"Hematol Oncol Clin N Am"},{"issue":"3","key":"6324_CR9","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/hon.3075","volume":"41","author":"T Chen","year":"2023","unstructured":"Chen T et al (2023) TAFRO syndrome: A disease that known is half cured. Hematol Oncol 41(3):310\u2013322. https:\/\/doi.org\/10.1002\/hon.3075","journal-title":"Hematol Oncol"},{"issue":"21","key":"6324_CR10","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1182\/blood.2023020009","volume":"141","author":"H Zhao","year":"2023","unstructured":"Zhao H et al (2023) A phase 2 prospective study of bortezomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed iMCD. Blood 141(21):2654\u20132657. https:\/\/doi.org\/10.1182\/blood.2023020009","journal-title":"Blood"},{"issue":"11","key":"6324_CR11","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1111\/jcmm.17251","volume":"26","author":"AD Phillips","year":"2022","unstructured":"Phillips AD et al (2022) Increased mTORC2 pathway activation in lymph nodes of iMCD-TAFRO. J Cell Mol Med 26(11):3147\u20133152. https:\/\/doi.org\/10.1111\/jcmm.17251","journal-title":"J Cell Mol Med"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06324-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06324-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06324-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T03:13:43Z","timestamp":1746414823000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06324-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["6324"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06324-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"assertion":[{"value":"14 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Written, informed consent was obtained from the patients to use the content and imaging material for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}